Tozorakimab Cuts COPD Exacerbations by Up to 34% in Phase 3 Trials Manuela Callari

https://www.medscape.com/viewarticle/tozorakimab-cuts-copd-exacerbations-34-phase-3-trials-2026a10010g0?ecd=wnl_edit_tpal_etid8749234&uac=148436CN&impID=8749234 BARCELONA, Spain — Add-on treatment with tozorakimab, a first-in-class monoclonal antibody targeting interleukin-33 (IL-33), significantly reduces the yearly rate of moderate and severe COPD exacerbations in patients receiving stable standard-of-care inhaled maintenance therapy. Results from the replicate phase 3 OBERON and TITANIA trials, presented at the European Respiratory Society (ERS) 2026 International Congress and simultaneously published in The New England Journal of Medicine, demonstrated up to a 34% vs ~30% reduction in exacerbations among former smokers vs the overall study population. Efficacy was observed regardless of baseline blood eosinophil counts (BECs), airflow obstruction severity, or smoking status.